ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

284
Analysis
Health Care • Hong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
bullish•Cross Asset Strategy
•27 Nov 2018 05:23

EM Health Care:  Late Cycle Rotation

Emerging Market Health Care allocations sit towards the lower end of their 7-year range. Current levels are off their 2015 highs by a margin, with...

Logo
439 Views
Share
bearish•Ascletis Pharma Inc
•22 Jul 2018 16:09

Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation

Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...

Logo
914 Views
Share
•26 Jun 2018 15:55

Trade Risks Start to Impact, as China Biotech Ambitions Grow…

Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...

Logo
257 Views
Share
•24 Mar 2017 16:32

Energy Medicine. Personal Experience. Impact. Growth in Asia. Ideas

This is an invest-able idea at the private level  with long term benefits. Both for the body, and for other ideas as well.Ever since I turned over...

Share
•25 Oct 2016 12:40

Key Drivers of Asia's Healthcare Sector

From a demand perspective, Asia’s population is growing as is longevity. On the supply side, Asia’s number of doctors, nurses, hospitals and...

Share
x